title: Therapy of peritoneal carcinomatosis of human colon cancer xenografts with yttrium 90-labeled anti-carcinoembryonic antigen antibody ZCE025.
abstract: The present study was undertaken to determine whether an anti-carcinoembryonic antigen (CEA) monoclonal antibody (MAB), labeled with the potent beta emitter yttrium 90, could alter the growth of diffuse intraperitoneal carcinomatosis of colon cancer. Nude mice bearing the CEA-producing human tumor line LS174T received therapy with the anti-CEA MAB ZCE025 90Y. Animals were evaluated 12 days after therapy. Untreated animals had a mean (+/- SEM) tumor burden of 3.99 +/- 0.10 g, while animals treated with ZCE025 90Y had 0.29 +/- 0.04 g present. This decrease was significant compared with the 1.31 +/- 0.16 g of tumor present in animals treated with a 90Y-labeled nonspecific antibody 96.5c. The therapeutic effects seen with ZCE025 90Y suggest a potentially useful role for 90Y-labeled anti-CEA MABs in the treatment of gastrointestinal carcinomatosis.
authors: Department of General Oncologic Surgery, City of Hope National Medical Center, Duarte, CA 91010.
authors: D M
authors: DM
authors: Hyams
authors: J M
authors: JM
authors: Esteban
authors: C P
authors: CP
authors: Lollo
authors: B G
authors: BG
authors: Beatty
authors: J D
authors: JD
authors: Beatty
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002272:Carcinoembryonic Antigen / Q000276:immunology*; D003110:Colonic Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D010534:Peritoneal Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D014183:Transplantation, Heterologous; D015021:Yttrium Radioisotopes / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D002272:Carcinoembryonic Antigen; D015021:Yttrium Radioisotopes